Purpura fulminans is a thrombotic disease that can occur during infections, disseminated intravascular coagulation or in the context of an acquired or congenital protein C or S deficiency. Here we report the case of a 4-year-old child who developed, 5 days after a chickenpox infection, large painful ecchymotic, necrotizing and retiform plaques on the lower extremities. Laboratory analyses revealed very low protein S levels as well as anticardiolipin antibodies. Aggressive treatment by low-molecular-weight heparin, steroids, intravenous immunoglobulins and fresh frozen plasma was able to prevent the extension of the lesions and to correct the coagulation abnormalities. No lesions required skin grafting. As in our patient, an acquired protein S deficiency is probably responsible for most cases of purpura fulminans occurring after varicella, but the concomitant presence of antiphospholipid antibodies may also play a role.

1.
Phillips WG, Marsden JR, Hill FG: Purpura fulminans due to protein S deficiency following chickenpox. Br J Dermatol 1992;127:30–32.
2.
Nguyen P, Reynaud J, Pouzol P, Munzer M, Richard O, François P: Varicella and thrombotic complications associated with transient protein C and protein S deficiencies in children. Eur J Pediatrics 1994;153:646–649.
3.
Levin M, Eley B, Louis J, Cohen H, Young L, Heyderman R: Postinfectious purpura fulminans caused by an autoantibody directed against protein S. J Pediatr 1995;127:355–363.
4.
Manco-Johnson M, Nuss R, Key N, Moertel C, Jacobson L, Meech S, Weinberg A, Lefkowitz J: Lupus anticoagulant and protein S deficiency in children with postvaricalla purpura fulminans or thrombosis. J Pediatr 1996;128:319–323.
5.
Kayemba Kay’s S, François P, Pollack B, Moutet F, Cussac E, Bost M: Localised thrombotic purpura: A rare complication of chickenpox. J Pediatr 1997;130:655–657.
6.
Woods CR, Johnson CA: Varicella purpura fulminans associated with heterozygosity for factor V Leiden and transient protein S deficiency. Pediatrics 1998;102:1208–1210.
7.
Van Ommen CH, van Wijnen M, de Groot FG, van der Horst CM, Peters M: Postvaricella purpura fulminans caused by acquired protein S deficiency resulting from antiprotein S antibodies: Search for the epitopes. J Pediatr Hematol Oncol 2002;24:413–416.
8.
Canpolat C, Bakir M: A case of purpura fulminans secondary to transient protein C deficiency as a complication of chickenpox infection. Turk J Pediatr 2002;44:148–151.
9.
Dahlbäck B: Blood coagulation. Lancet 2000;355:1627–1632.
10.
D’Angelo A, Della Valle P, Crippa L, Pattarini E, Grimaldi L, Vigano D’Angelo S: Autoimmune protein S deficiency in a boy with severe thromboembolic disease. N Engl J Med 1993;328:1753–1757.
11.
Viseux V, Darnige L, Carmi E, Chaby G, Poulain JF, Cevallos R, Lok C, Denoeux JP: Pulmonary embolism and transitory ant-B2GPI antibodies in an adult with chickenpox. Lupus 2000;9:558–560.
12.
Ieko M, Sawada KI, Koike T, Notoya A, Mukai M, Kohno M, et al: The putative mechanism of thrombosis in antiphospholipid syndrome: Impairment of the protein C and the fibrinolytic systems by monoclonal anticardiolipin antibodies. Semin Thromb Hemost 1999;25:503–507.
13.
Josephson C, Nuss R, Jacobson L, Hacker MR, Murphy J, Weinberg A, Manco-Johnson MJ: The varicella-autoantibody syndrome. Pediatr Res 2001;50:345–352.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.